JPWO2021022256A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021022256A5 JPWO2021022256A5 JP2022506485A JP2022506485A JPWO2021022256A5 JP WO2021022256 A5 JPWO2021022256 A5 JP WO2021022256A5 JP 2022506485 A JP2022506485 A JP 2022506485A JP 2022506485 A JP2022506485 A JP 2022506485A JP WO2021022256 A5 JPWO2021022256 A5 JP WO2021022256A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- subject
- paclitaxel
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881894P | 2019-08-01 | 2019-08-01 | |
| US62/881,894 | 2019-08-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
| USPCT/US2020/031181 | 2020-05-01 | ||
| PCT/US2020/044777 WO2021022256A1 (en) | 2019-08-01 | 2020-08-03 | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022543780A JP2022543780A (ja) | 2022-10-14 |
| JP2022543780A5 JP2022543780A5 (https=) | 2023-08-10 |
| JPWO2021022256A5 true JPWO2021022256A5 (https=) | 2023-08-10 |
| JP7703513B2 JP7703513B2 (ja) | 2025-07-07 |
Family
ID=74229293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506485A Active JP7703513B2 (ja) | 2019-08-01 | 2020-08-03 | 抗ガレクチン９抗体と化学療法剤の組合せがん治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220332832A1 (https=) |
| EP (1) | EP4007640A4 (https=) |
| JP (1) | JP7703513B2 (https=) |
| CN (1) | CN114502241B (https=) |
| AU (1) | AU2020319899B2 (https=) |
| CA (1) | CA3149324A1 (https=) |
| WO (1) | WO2021022256A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020223704A1 (en) * | 2019-05-01 | 2020-11-05 | New York University | Anti-galectin-9 antibodies and uses thereof |
| JP2024519450A (ja) * | 2021-04-30 | 2024-05-14 | ピュアテック・エル・ワイ・ティ・インコーポレイテッド | 抗ガレクチン－９抗体及びその治療的使用 |
| WO2022232653A1 (en) * | 2021-04-30 | 2022-11-03 | Puretech Lyt, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| CN113624965B (zh) * | 2021-08-05 | 2024-02-09 | 中国人民解放军军事科学院军事医学研究院 | N蛋白特异性IgG4在甄别新型冠状病毒感染者和疫苗接种者中的应用 |
| CA3233331A1 (en) * | 2021-10-01 | 2023-04-06 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| CN119286974A (zh) * | 2024-12-12 | 2025-01-10 | 南方医科大学南方医院 | 一种晚期结直肠癌靶向治疗预测模型的构建系统 |
| CN120585880B (zh) * | 2025-08-07 | 2025-12-09 | 四川大学华西医院 | 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| FR3021970B1 (fr) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| WO2016008005A1 (en) * | 2014-07-14 | 2016-01-21 | The Council Of The Queensland Institute Of Medical Research | Galectin immunotherapy |
| CN110248674B (zh) * | 2016-09-07 | 2021-10-26 | 萨辛生命科学有限公司 | 针对vegf的合成抗体及其用途 |
| SG11202001606XA (en) * | 2017-09-13 | 2020-03-30 | Five Prime Therapeutics Inc | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| IL312910B1 (en) * | 2017-10-27 | 2026-02-01 | Univ New York | Anti-galectin-9 antibodies and their uses |
-
2020
- 2020-08-03 US US17/631,378 patent/US20220332832A1/en active Pending
- 2020-08-03 CN CN202080068359.6A patent/CN114502241B/zh active Active
- 2020-08-03 CA CA3149324A patent/CA3149324A1/en active Pending
- 2020-08-03 JP JP2022506485A patent/JP7703513B2/ja active Active
- 2020-08-03 EP EP20846431.3A patent/EP4007640A4/en active Pending
- 2020-08-03 WO PCT/US2020/044777 patent/WO2021022256A1/en not_active Ceased
- 2020-08-03 AU AU2020319899A patent/AU2020319899B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2020508317A5 (https=) | ||
| JP2019503349A5 (https=) | ||
| JP2018527383A5 (https=) | ||
| JP2021510697A5 (https=) | ||
| JPWO2021022256A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| US11648310B2 (en) | Combination of anti-FGFR4-antibody and bile acid sequestrant | |
| JP2007531728A5 (https=) | ||
| WO2025061110A1 (zh) | 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途 | |
| WO2025103379A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JPWO2020223702A5 (https=) | ||
| WO2024230772A1 (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| CN119789867A (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 | |
| JPWO2022232653A5 (https=) | ||
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| JPWO2023041622A5 (https=) | ||
| HK40122430A (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| RU2025136351A (ru) | Способ лечения солидных опухолей с помощью конъюгата антитело-лекарственное средство, нацеленного на клаудин 18.2 | |
| JPWO2023057534A5 (https=) | ||
| AU2024344603A1 (en) | Use of anti-b7h3 antibody-drug conjugate in preparation of drug for treating nasopharyngeal carcinoma and/or lymphoepithelioma-like carcinoma | |
| JPWO2023056461A5 (https=) |